<p>COMPASS Pathways（纳斯达克代码：CMPS - 获取免费报告）于周四发布了季度财报。公司报告本季度每股收益为（$0.38），低于分析师一致预期的（$0.37），差距为（$0.01），据 Zacks 报道。</p>
<p>获取 <strong>COMPASS Pathways</strong> 警报：</p>
<h2>COMPASS Pathways 股价下跌 0.2%</h2>
<p>周五午盘交易中，纳斯达克：CMPS 的股票下跌了 $0.01，报 $4.34。该股票交易量为 2,524,177 股，而其平均交易量为 2,277,808 股。该公司的市值为 $4.0605 亿，市盈率为 -2.36，贝塔值为 2.16。公司的债务与股本比率为 0.11，速动比率为 10.18，流动比率为 10.18。该业务的 50 日移动平均价格为 $3.99，200 日移动平均价格为 $3.80。COMPASS Pathways 的 12 个月低点为 $2.25，12 个月高点为 $8.54。</p>
<h2>分析师设定新目标价</h2>
<p>CMPS 一直是几份研究分析报告的主题。Evercore ISI 在 6 月 23 日的研究报告中重申了 “持平” 评级，并将 COMPASS Pathways 的目标价下调至 $6.00（之前为 $11.00）。HC Wainwright 在 7 月 15 日的研究报告中重申了 “买入” 评级，并将 COMPASS Pathways 的目标价设定为 $45.00。Canaccord Genuity Group 在周五的研究报告中重申了 “买入” 评级，并将 COMPASS Pathways 的目标价设定为 $15.00。最后，Cantor Fitzgerald 在 5 月 27 日的研究报告中重申了 “增持” 评级，并将 COMPASS Pathways 的目标价设定为 $12.00。一位分析师对该股票给予了持有评级，六位分析师给予了买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 $17.00。</p>
<p><strong>阅读我们关于 CMPS 的最新研究报告</strong></p>
<h2>COMPASS Pathways 的机构交易</h2>
<p>一家机构投资者最近增加了在 COMPASS Pathways 股票中的持仓。根据该公司在最近向证券交易委员会提交的 13F 表格，皇家加拿大银行在第一季度将其在 COMPASS Pathways PLC 赞助的 ADR（纳斯达克：CMPS - 免费报告）中的持仓提高了 49.8%。该基金在此期间购买了额外的 29,733 股后，持有该公司 89,446 股股票。根据其最近向证券交易委员会提交的文件，皇家加拿大银行持有的 COMPASS Pathways 股票约占 0.10%，价值 $256,000。机构投资者和对冲基金持有该公司 46.19% 的股票。</p>
<h2>COMPASS Pathways 公司简介</h2>
<p>（获取免费报告）</p>
<p>COMPASS Pathways plc 在英国和美国运营，作为一家心理健康护理公司。它开发的 COMP360 是一种正在进行 III 期临床试验的迷幻蘑菇治疗，用于治疗难治性抑郁症；并且正在进行 II 期临床试验，用于治疗创伤后应激障碍和神经性厌食症。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而非 COMPASS Pathways</li>
<li>如何投资科技股及值得考虑的顶级科技股</li>
<li>比特币与股息：这三只 ETF 的赢家组合</li>
<li>投资石油股的方式与原因</li>
<li>PG&amp;E 是 AI 的投资机会吗？为何期权交易者在大举押注</li>
<li>如何在购买前评估一只股票</li>
<li>MarketBeat 周报 – 07/28 - 08/01</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QUw"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 COMPASS Pathways 吗？</h2>
<p>在考虑 COMPASS Pathways 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 COMPASS Pathways 并不在名单上。</p>
<p>尽管 COMPASS Pathways 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CMPS

<p>COMPASS Pathways（纳斯达克代码：CMPS）报告季度每股收益为（$0.38），低于预期$0.01。该股下跌 0.2%，报$4.34，市值为 4.0605 亿美元。分析师对其评级不一，普遍目标价为$17.00。机构投资者持有该公司 46.19% 的股份，该公司专注于用于心理健康状况的迷幻蘑菇治疗。尽管评级为适度买入，COMPASS Pathways 并不是分析师推荐的顶级股票之一</p>

<p>COMPASS Pathways (NASDAQ:CMPS - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01), Zacks reports.</p>
<div class="lb-trans"><p>COMPASS Pathways（纳斯达克代码：CMPS - 获取免费报告）于周四发布了季度财报。公司报告本季度每股收益为（$0.38），低于分析师一致预期的（$0.37），差距为（$0.01），据 Zacks 报道。</p>
</div><p>Get <strong>COMPASS Pathways</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>COMPASS Pathways</strong> 警报：</p>
</div><h2>COMPASS Pathways Trading Down 0.2%</h2>
<div class="lb-trans"><h2>COMPASS Pathways 股价下跌 0.2%</h2>
</div><p>Shares of NASDAQ:CMPS traded down $0.01 during midday trading on Friday, hitting $4.34. 2,524,177 shares of the stock were exchanged, compared to its average volume of 2,277,808. The stock has a market capitalization of $406.05 million, a price-to-earnings ratio of -2.36 and a beta of 2.16. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.18 and a current ratio of 10.18. The business's 50-day moving average price is $3.99 and its 200 day moving average price is $3.80. COMPASS Pathways has a 12 month low of $2.25 and a 12 month high of $8.54.</p>
<div class="lb-trans"><p>周五午盘交易中，纳斯达克：CMPS 的股票下跌了 $0.01，报 $4.34。该股票交易量为 2,524,177 股，而其平均交易量为 2,277,808 股。该公司的市值为 $4.0605 亿，市盈率为 -2.36，贝塔值为 2.16。公司的债务与股本比率为 0.11，速动比率为 10.18，流动比率为 10.18。该业务的 50 日移动平均价格为 $3.99，200 日移动平均价格为 $3.80。COMPASS Pathways 的 12 个月低点为 $2.25，12 个月高点为 $8.54。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>CMPS has been the topic of several research analyst reports. Evercore ISI reaffirmed an &#34;in-line&#34; rating and issued a $6.00 price objective (down from $11.00) on shares of COMPASS Pathways in a research note on Monday, June 23rd. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $45.00 target price on shares of COMPASS Pathways in a research report on Tuesday, July 15th. Canaccord Genuity Group reiterated a &#34;buy&#34; rating and issued a $15.00 target price on shares of COMPASS Pathways in a research report on Friday. Finally, Cantor Fitzgerald reiterated an &#34;overweight&#34; rating and issued a $12.00 target price on shares of COMPASS Pathways in a research report on Tuesday, May 27th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $17.00.</p>
<div class="lb-trans"><p>CMPS 一直是几份研究分析报告的主题。Evercore ISI 在 6 月 23 日的研究报告中重申了 “持平” 评级，并将 COMPASS Pathways 的目标价下调至 $6.00（之前为 $11.00）。HC Wainwright 在 7 月 15 日的研究报告中重申了 “买入” 评级，并将 COMPASS Pathways 的目标价设定为 $45.00。Canaccord Genuity Group 在周五的研究报告中重申了 “买入” 评级，并将 COMPASS Pathways 的目标价设定为 $15.00。最后，Cantor Fitzgerald 在 5 月 27 日的研究报告中重申了 “增持” 评级，并将 COMPASS Pathways 的目标价设定为 $12.00。一位分析师对该股票给予了持有评级，六位分析师给予了买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 $17.00。</p>
</div><p><strong>Read Our Latest Research Report on CMPS</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CMPS 的最新研究报告</strong></p>
</div><h2>Institutional Trading of COMPASS Pathways</h2>
<div class="lb-trans"><h2>COMPASS Pathways 的机构交易</h2>
</div><p>An institutional investor recently raised its position in COMPASS Pathways stock. Royal Bank of Canada lifted its position in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 49.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 89,446 shares of the company's stock after purchasing an additional 29,733 shares during the period. Royal Bank of Canada owned about 0.10% of COMPASS Pathways worth $256,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 46.19% of the company's stock.</p>
<div class="lb-trans"><p>一家机构投资者最近增加了在 COMPASS Pathways 股票中的持仓。根据该公司在最近向证券交易委员会提交的 13F 表格，皇家加拿大银行在第一季度将其在 COMPASS Pathways PLC 赞助的 ADR（纳斯达克：CMPS - 免费报告）中的持仓提高了 49.8%。该基金在此期间购买了额外的 29,733 股后，持有该公司 89,446 股股票。根据其最近向证券交易委员会提交的文件，皇家加拿大银行持有的 COMPASS Pathways 股票约占 0.10%，价值 $256,000。机构投资者和对冲基金持有该公司 46.19% 的股票。</p>
</div><h2>COMPASS Pathways Company Profile</h2>
<div class="lb-trans"><h2>COMPASS Pathways 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.</p>
<div class="lb-trans"><p>COMPASS Pathways plc 在英国和美国运营，作为一家心理健康护理公司。它开发的 COMP360 是一种正在进行 III 期临床试验的迷幻蘑菇治疗，用于治疗难治性抑郁症；并且正在进行 II 期临床试验，用于治疗创伤后应激障碍和神经性厌食症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than COMPASS Pathways</li>
<li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li>
<li>Bitcoin and Dividends: A Winning Combo in These 3 ETFs</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Is PG&amp;E an AI Power Play? Why Options Traders Are Betting Big</li>
<li>How to Evaluate a Stock Before Buying</li>
<li>MarketBeat Week in Review – 07/28 - 08/01</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 COMPASS Pathways</li>
<li>如何投资科技股及值得考虑的顶级科技股</li>
<li>比特币与股息：这三只 ETF 的赢家组合</li>
<li>投资石油股的方式与原因</li>
<li>PG&amp;E 是 AI 的投资机会吗？为何期权交易者在大举押注</li>
<li>如何在购买前评估一只股票</li>
<li>MarketBeat 周报 – 07/28 - 08/01</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CMPS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in COMPASS Pathways Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 COMPASS Pathways 吗？</h2>
</div><p>Before you consider COMPASS Pathways, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 COMPASS Pathways 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 COMPASS Pathways 并不在名单上。</p>
</div><p>While COMPASS Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 COMPASS Pathways 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Compass Pathways（纳斯达克代码：CMPS）公布了财报结果，每股收益比预期低 0.01 美元